In exiting recent news, Canadian researchers identified the mechanism of action of cannabidiol for pain relief without side effects
A team of scientists from the McGill University announced news for people affected by chronic pain. They showed that appropriate doses of cannabidiol (CBD) extracted from the cannabis plant can be used to relieve pain safely and without causing the typical high state produced by THC. The results of their study were published in the scientific journal PAIN (The Journal of the International Association for the Study of Pain).
Indica cannabis and Sativa cannabis are the two main cannabis strains that underlie the pharmacological principles known as tetrahydrocannabinol (THC) and cannabidiol (CBD). Dr. Gabriella Gobbia’s team demonstrated that CBD does not act on cannabinoid type 1 (CB1) receptors such as THC, but through the mechanism that binds the specific receptors involved in anxiety (5-HT1A) and pain (TRPV1). The researchers were also able to extrapolate the exact dosage of CBD showing analgesic and anxiolytic properties without the risk of dependence and without causing the euphoria usually produced by THC.
“We have found that in animal models of chronic or neuropathic pain, low doses of CBD administered for seven days relieve pain and anxiety, two symptoms often associated with this condition,” says Danilo De Gregorio, a postdoctoral fellow at McGill University in
Dr.Gobbi’s laboratory and the study’s first author.”
The study’s lead author, Dr. Gobbi, a researcher with the Brain Repair and Integrative Neuroscience Program at Mc Gill, sees today’s results as a breakthrough in the evidence-based medical application of cannabis. CBD could provide a safe alternative to THC and opioids for the treatment of chronic pain, such as sciatic neuralgia, back pain, diabetes, cancer or post-traumatic pain.
“Our findings shed light on the mechanism of action of CBD; they demonstrate that it can be used as a drug without producing the dangerous side effects associated with THC,” says Dr. Gobbi, who is also a professor of psychiatry in the Faculty of Medicine at McGill University and a psychiatrist at the MUHC. The research we have conducted represents a new breakthrough in the evidence-based medical application of cannabis.”